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T he long-term event-free survival (EFS) of ana-plastic large-cell lymphoma (ALCL) in children is 
about 70%.  About 30% of all ALCL cases in children 
are relapsed/refractory cases [1].  No standard treatment 
for these relapsed/refractory cases has been established.
A previous study reported that vinblastine mono-
therapy had an objective response rate of 86% and a 
complete remission rate of 56% in patients with ALCL,  
but the long-term EFS rate was only about 30% [2].  
Hematopoietic stem cell transplantation (HSCT) is a 
curative treatment option in relapsed/refractory ALCL.  
However,  the effectiveness and safety of this approach 
have been examined in only a few studies with a limited 
number of cases.  As for allogeneic transplantation,  the 
Center for International Blood and Marrow Transplant 
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No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established.  
This study is a multicenter,  open-label trial to examine the effectiveness and safety of transplantation with 
reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL.  We 
defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) 
for two days and total body irradiation at 4 Gy,  followed by allogeneic hematopoietic stem cell transplantation.  
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Research in the USA reported a 5-year EFS rate of 46% 
and a 5-year cumulative relapse rate of 20% in 12 patients 
[3].  In France,  results were reported for 34 allogeneic 
transplantation patients aged 18 years or younger and 
adolescents with relapsed/refractory anaplastic lym-
phoma kinase (ALK)-positive ALCL,  and they similarly 
showed a 5-year EFS rate of 58% and a 5-year cumula-
tive relapse rate of 18% [4].  In Japan,  the results for 
relapsed/refractory child cases based on the Transplant 
Registration Unified Management Program (TRUMP) 
data of the Japan Hematopoietic Cell Transplantation 
Society were also similar to those of the reports from 
overseas,  with a 5-year EFS rate after autologous trans-
plantation of 38%,  a 5-year cumulative relapse rate of 
49%,  a 5-year EFS rate after allogeneic transplantation 
of 50%,  and a 5-year cumulative relapse rate of 28% [5].  
Although the cumulative relapse rate was lower in allo-
geneic transplantation compared to autologous trans-
plantation,  treatment-related death was a problem in 
allogeneic transplantation,  and the 5-year cumulative 
treatment-related mortality rates from the TRUMP data 
were 12% for autologous transplantation and 25% for 
allogeneic transplantation.
In recent years,  ALK inhibitors such as crizotinib,  
alectinib,  ceritinib,  and an anti-CD30 antibody,  bren-
tuximab vedotin (BV),  have been developed as molec-
ular target therapeutic agents for ALCL,  and a positive 
impact on relapsed or refractory ALCL in children is 
expected.  However,  the current treatment is to intro-
duce a single agent to achieve (re-)remission.  In addi-
tion,  information on the safety of crizotinib and BV is 
based on a phase I study,  and there is no information 
on their safety and efficacy over the course of long-term 
administration.  With these new drugs,  intensive/con-
solidation therapy that achieves (re-)remission is con-
sidered to be a basis for allogeneic HSCT.  Allogeneic 
HSCT following crizotinib monotherapy for relapsed/
refractory ALCL in 6 patients was reported with the 
following results: 5 patients remained in remission,  
and 1 patient developed isolated central nervous system 
relapse [6].  In this study,  we defined reduced-intensity 
conditioning (RIC) as total body irradiation (TBI) 4 Gy 
+ fludarabine 150 mg/m2 plus melphalan 140 mg/m2 in 
accordance with 2 previous representative definitions 
[7 , 8].  The aim of the present study was to examine the 
effectiveness and safety of RIC for patients under 
20 years old with relapsed or refractory ALCL.
Endpoints
Primary endpoints. The primary outcome is the 
proportion of one-year EFS after transplantation.  
Events are defined as all-cause death,  relapse,  progres-
sion,  re-transplantation,  secondary neoplasm (includ-
ing myelodysplastic syndrome: MDS),  and stabiliza-
tion at one year after transplantation.  If observation is 
discontinued within one year,  it will be treated as an 
event.
Secondary endpoints
•  Overall survival (up to 2 years after transplanta-
tion)
We define overall survival as the duration from the 
date of transplantation to the date of all-cause death.  If 
an event occurs before transplantation,  we will consider 
it to be an event on the start date.  Survivors will be cen-
sored on the last observation date.
•  EFS (up to 2 years after transplantation)
We define EFS as the duration from the date of 
transplantation to the date of the first event confirmed,  
including all-cause death,  relapse,  progression,  reim-
plantation,  secondary neoplasm (including MDS),  or 
stabilization at one year after transplantation.  If an 
event occurs before transplantation or if the ALCL does 
not remit even after transplantation during a stable state 
at one year after transplantation,  we will treat it as an 
event on the start date.  Survivors will be censored on 
the last observation date.
•  Cumulative relapse rate (up to 2 years after trans-
plantation)
We define the time to cumulative relapse as the 
duration from the date of transplantation to the date of 
the examination that confirmed either relapse after 
transplantation,  progression,  or stabilization at one 
year after transplantation.  If an event occurs before 
transplantation,  or if the ALCL does not remit after 
transplantation in a stable state at one year after trans-
plantation,  we will treat it as an event on the start date.  
Survivors will be censored on the last observation date.  
We will calculate the cumulative relapse rate with the 
competing risk of death that does not depend on the 
original disease up to relapse after transplantation and 
re-transplantation.
•  Neutrophil engraftment graft status after transplan-
tation
We define engraftment as the number of neutrophils 
(calculated from the number of white blood cells × the 
?? ??????????? ????????? ????????????? ???? ???? ??
neutrophil percentage) reaching 500/μL or more on 
consecutive examination days with 3 or more time 
points,  with this first day as the engraftment date.  Also,  
if recovery of hematopoietic function occurs after 
28 days due to another cause such as infection,  and the 
donor type is confirmed by chimeric examination,  we 
will treat this as delayed engraftment.
•  Treatment-related death after transplantation
•  Incidence and severity of acute graft versus host 
disease (GVHD)
•  Incidence and severity of chronic GVHD
•  Frequency,  number of cells,  and reasons for con-
ducting donor lymphocyte infusion
•  Frequency of re-transplantation
•  Chimeric analysis (30 days and 100 days after 
transplantation)
•  Toxicity from the start date of RIC to four weeks 
after transplantation
•  Days in a febrile state of more than 38 degrees up 
to 100 days after transplantation
•  Adverse events occurring at 100 days,  one year,  
and two years after transplantation
Treatment Methods
Study design. This study is a multicenter,  
open-label,  clinical trial.  As it was impossible to set a 
concurrent control group due to the small number of 
patients,  we designed it as a single-arm study.  In addi-
tion,  we will decide on early discontinuation of this 
study using the Bayesian method proposed by Thall and 
Simon [9]; this approach has the characteristics which 
enable to make sequential decisions whether a treat-
ment is promising while taking account for uncertainty 
of response rates.  This study was approved by the 
National Hospital Organization Review Board for 
Clinical Trials (Nagoya) in May 2019 and is registered 
in the Japan Registry of Clinical Trials (registry num-
ber: jRCTs041190066).
Participants. We will register patients who satisfy 
all the inclusion criteria shown in Table 1 and who do 
not meet any of the exclusion criteria.  We will conduct 
registration using an electronic data capture system that 
issues registration numbers.  This is an open-label study.
Interventions. The administration schedule is 
shown in Table 2.  Fludarabine 30 mg/m2/day will be 
administered on day －7 to day －3.  The dose will be 
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????? ?　 Eligibility criteria
Inclusion criteria
(1)  With anaplastic large cell lymphoma aged 19 years or younger at the time of registration
(2)  Remission cannot be achieved by ﬁrst-time chemotherapy,  or relapse after chemotherapy and autologous transplantation
(3)  With indication for hematopoietic cell transplantation
(4)  With ECOG Performance status of 0︲2
(5)  With organ functions satisfying all the following criteria within 21 days before registration:
(5-a)  no uncontrolled heart failure,  and a left ventricular ejection fraction of 50% or more;
(5-b)  forced expiratory volume (FEV) 1.0% of 50% or more and predicted vital capacity 50% or more.  If a lung test is impossible,  SpO2
≥95% without the need for oxygen administration;
(5-c)  AST/ALT of less than 5×ULN (CTCAE grade 2 or less) and total bilirubin 3×ULN (CTCAE grade 2 or less);
(5-d)  no uncontrolled renal failure,  and less than 2×ULN serum creatinine.
(6)  have been registered in the JPLSG prospective study (JPLSG-CHM-14)
(7)  have obtained written informed consent (including assent) from representatives/themselves for participation in this study
Exclusion criteria
(1)  With central nervous system inﬁltration at the time of ﬁrst symptoms or relapse
(2)  With a history of allogeneic hematopoietic stem cell transplantation and organ transplantation
(3)  With uncontrollable infection
(4)  With congenital diseases or psychiatric disorders that interfere with study treatment
(5)  With multiple cancers
(6)  With a history of hypersensitivity to drugs used in RIC or drugs used to prevent acute GVHD
(7)  With a possibility of pregnancy or being pregnant
(8)  Judged inappropriate to receive the study treatment by the attending doctor
1 mg/kg/day if a patient is under 1 year old or weighs 
less than 10 kg.  Melphalan 70 mg/m2/day will be 
administered on day －7 and day －6.  The dose will be 
2.3 mg/kg/day if a patient is under 1 year old or weighs 
less than 10 kg.  We will perform TBI 4 Gy on day －1.  
Replacing TBI with total marrow irradiation is not per-
missible.  However,  performing TBI on day －8,  day －2,  
or day 0 is allowed.  We define these treatments as RIC.  
We will perform allogeneic HSCT on day 0 after the 
treatments.  The source of transplanted cells will largely 
be bone marrow and cord blood,  but peripheral blood 
is also acceptable.  The treatment period for each study 
subject is about one week,  and the follow-up period is 
two years.
Combination Therapy
•  Recommended combination therapy/supportive 
therapy
1) Antiemetics including steroids.  2) Use of granu-
locyte colony-stimulating factor after transplantation.  
3) During the period of bone marrow suppression by 
this treatment protocol,  a sufficient countermeasure 
against infectious diseases must be taken to help prevent 
infection (the administration of prophylactic antibiot-
ics,  antifungals,  or antivirals) at each institution during 
stem cell transplantation.
•  Unacceptable combination therapy
1) Donor lymphocyte infusion accompanied by the 
administration of anti-cancer drugs.  2) A combination 
of treatments aimed at enhancing immunological 
anti-tumor effects other than donor lymphocyte infu-
sion.  3) Use of anticancer drugs including a molecular 
target after transplantation for primary disease.  
However,  the indication for molecular-targeted drugs 
before the start of the pre-transplant treatment can be 
determined at the institution.  4) Multiple cord blood 
transplantation.
Statistical Considerations
Sample size. Because patient recruitment will 
likely be extremely difficult in this study,  we will use the 
Bayesian method proposed by Thall and Simon [9].  
Hereinafter,  we will describe the proportion of one-year 
EFS after transplantation as the response rate.
Setting the prior distribution of the response rate.
We assume the beta distribution Beta (a , b) in the prior 
distribution of the effective threshold and expected 
response rate.  An analysis of relapsed and refractory 
ALCL in Japan using TRUMP data revealed that the 
response rate was 50% in 24 patients in whom alloge-
neic HSCT was performed [5].  Reports of allogeneic 
HSCT in relapsed/refractory ALCL from the United 
States and France also described 5-year EFS rates of 
46% and 58%,  respectively,  similar to the results from 
Japan [3 , 4].  Because most incidences of relapse after 
ALCL transplantation occur within one year,  it is 
assumed that the response rate and the 5-year EFS rate 
are equivalent.  Previous reports used myeloablative 
conditioning,  whereas in this study RIC will be per-
formed.  Even if the EFS rate is equivalent to the rates in 
these previous reports,  a reduction in therapeutic tox-
icity is expected.  Therefore,  we set the threshold rate at 
45%,  and candidates for the prior distribution of the 
threshold rate as Beta (29.7,  36.3) and Beta (13.0,  
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????? ?　 Administration schedule
Contents Method －7 －6 －5 －4 －3 －2 －1 0
Fludarabine 30 mg/m2/day for 5 days (30-minute infusion)
1 mg/kg/day for children under one year old or less than 10 kg
● ● ● ● ●
Melphalan 70 mg/m2/day for 2 days (30-minute infusion)
2.3 mg/kg/day for children under one year old or less than 10 kg 
Any two dosing days from day－7 to day－3 are acceptable
■ ■
TBI 4 Gy (testicular shield allowed but not an ovarian shield)
Dose rate of less than 20 cGy/min
Replacing TBI with total marrow irradiation is not acceptable.
Performing on day－8,  day－2 or day 0 is acceptable.
○
Transplantation Mainly using bone marrow and cord blood.
Peripheral blood is also acceptable.
⁂
15.9).  According to the method of Thall and Simon,  we 
determined the parameters a and b so that the width of 
the 90% probability interval running from the 5th to 
the 95th percentiles in the prior distribution became 0.2 
or 0.3,  below the average of 0.45.
In the analysis of relapsed/refractory ALCL in Japan 
using the TRUMP data,  the response rate in the RIC 
group was 75% (3/4).  In Italy,  a phase II prospective 
study of allogeneic HSCT using RIC was performed in 
117 adults with peripheral T cell lymphoma,  including 
four ALK-negative ALCL patients,  and the 3-year pro-
gression-free survival rate was 64% [10].  Based on 
these results,  we set the expected response rate in this 
study to 70%.  From these,  for a case in whom the δ0 of 
improvement over the threshold using the Thall and 
Simon method equals 0.25,  and the cE values for the 
sums of the 2 hyperparameters of the beta distribution 
are set to 2 and 4,  we determined the candidate for the 
prior distribution of the expected response rates to be 
Beta (1.15,  0.85),  and Beta (2.3,  1.7).
We defined the criterion for judging whether this 
therapy is effective as “a posterior probability of the 
response rate exceeding the threshold of 95% or more,” 
and that for determining that it is not effective as “a pos-
terior probability of the response rate exceeding the 
threshold of 1% or less.”
After calculating the number of boundaries in each 
scenario in which the prior distribution was changed,  
we calculated each of the following and evaluated the 
influence of the prior distribution: the probability that 
the development regimen is erroneously determined to 
be effective when the expected response rate is 45% the 
level of the threshold,  the probability that the regimen 
is judged to be not effective in the same situation,  the 
probability that the development regimen is judged to 
be effective when the value is 70% of the expected value,  
and the probability that the regimen is mistakenly 
judged to be not effective in the same situation.  As a 
result,  the difference in the number of boundaries 
between scenarios is at most one,  and when the mini-
mum number is set to 10,  in a scenario similar to the 
number of patients in sum of previous studies,  the 
probability of correctly judging the regimen to be effec-
tive was 0.77,  and the probability of incorrectly judging 
it to be effective was less than 0.10.  From the above,  we 
set the threshold response rate to 45% (prior distribu-
tion: Beta (29.7,  36.3)) and the expected response rate 
to 70% (prior distribution: Beta (2.3,  1.7)).  We will 
judge this treatment method to be effective when the 
posterior probability of the response rate exceeding the 
threshold is 95% or more.  If the posterior probability 
that the response rate exceeds the threshold is 1% or 
less,  we will judge this treatment to be ineffective.  The 
minimum number of cases will be 10,  and the maxi-
mum number will be 18.  Table 3 shows the sample size 
and number of response boundaries.
Interim analysis. Interim analysis will be per-
formed on the primary endpoint every time after the 
registration of the 10th patient in order to determine 
whether the treatment is effective and the study should 
be stopped,  the treatment is ineffective,  namely futility 
in the Table 3,  and the study should be stopped,  or the 
study continues.  If the number of responses in the 
patients to be evaluated is the same as or more than the 
response boundary for effective stop,  it will be judged as 
effective and the study should be stopped.  If the num-
ber is equal to or less than the response boundary of 
futility,  it will be judged as ineffective and study should 
be stopped.  Otherwise,  we will continue the study.
Statistical Consideration. We will analyze the 
response rate,  which is the primary endpoint when the 
data of all registered patients up to one year after trans-
plantation are fixed.  Then,  we will estimate the poste-
rior distribution of the response rate (posterior mean,  
95% credible interval with highest posterior density,  
probability of exceeding threshold).  For reference,  we 
will calculate point estimates and the 95% confidence 
interval (CI) of the response rate.
Analyses other than those of the primary endpoint 
will be done after the final follow-up data are fixed.  We 
will calculate Kaplan-Meier curves for overall survival 
and EFS,  and point estimates and CI for the two-year 
survival rate after transplantation.  We will estimate the 
cumulative incidence function using the competitive 
risk model and calculate point estimates and the CI of 
the 2-year cumulative incidence rate after transplanta-
tion.
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????? ?　 Sample size and number of response boundaries
Sample size 10 11 12 13 14 15 16 17 18
Response boundary 
for eﬀective stop
8 8 9 10 10 11 11 12 12
Response boundary 
for futility stop
2 3 3 4 4 5 5 6 6
Discussion
Only reports from Japan have indicated the effec-
tiveness of HSCT using RIC in ALCL [5].  In HSCT 
using RIC,  there is a concern that the relapse rate may 
increase following attenuation of the pretreatment 
intensity.  However,  there were 4 cases of allogeneic 
HSCT using RIC in the TRUMP data,  of which three 
were in non-remission at the time of transplantation,  
and all 3 of these cases achieved long-term survival in 
remission.  Although the number of cases was small,  
this result suggests the effectiveness of HSCT using RIC 
in relapsed/refractory ALCL.  ALCL relapse is common,  
and relapse often occurs after HSCT.  In cases for whom 
therapeutic toxicity is a concern,  using RIC has the 
potential to reduce the incidence of treatment-related 
death.
Few child/adolescent patients are indicated for 
hematopoietic cell transplantation in relapsed/refrac-
tory ALCL.  To make a clear treatment decision in such 
a situation,  we decided on early discontinuation of this 
study using the Bayesian method.  In this study,  we 
expect to further develop therapeutic methods in allo-
geneic HSCT using RIC in child/adolescent relapsed/
refractory ALCL.
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